# APBA Kısa Özet
A prospective observational study investigated the effects of oral antifungal therapy on microbiome dynamics in patients with inflammatory bowel disease (IBD) and mild oral thrush. Fluconazole, but not nystatin, significantly reduced intestinal Candida burden and reshaped gut fungal-community composition. Treatment was accompanied by increased bacterial diversity, expansion of short-chain fatty-acid-producing taxa, restoration of anti-inflammatory microbial metabolites, and durable shifts in cross-kingdom microbial networks. These microbiome and metabolomic changes coincided with improved disease activity indices and a decreased risk of disease progression over the 8‑week follow‑up period. The study provides early evidence that systemic antifungal therapy can influence the gut ecosystem in IBD.
# Çalışma neyi araştırdı?
The study aimed to evaluate whether targeted antifungal therapy could modify the gut mycobiome and associated bacterial communities in IBD patients with mild oral thrush, a condition indicating Candida overgrowth shared between the oral cavity and gut. Researchers compared two treatment approaches: oral nystatin (swish‑and‑spit, targeting the oral cavity only) and oral fluconazole (gastrointestinal and oral targeting). The investigation sought to determine if reducing intestinal Candida would translate into broader microbiome changes and clinical improvements, thereby testing the hypothesis that mycobiome modulation could be therapeutically relevant.
# Yöntem
This was a prospective observational study conducted at a single tertiary centre, involving 53 patients with mild‑to‑moderate ulcerative colitis or Crohn's disease who had mild oral thrush. Participants were allocated to two groups based on clinician choice: 18 received oral nystatin (swish‑and‑spit method, targeting oral Candida), and 35 received oral fluconazole (gastrointestinal and oral targeting). The study duration was 8 weeks. Baseline and follow‑up stool samples were collected for fungal ITS sequencing and bacterial 16S rRNA profiling, allowing assessment of community composition and diversity. Serum samples underwent untargeted metabolomic analysis to quantify microbial‑derived metabolites. Standard disease activity indices—such as the Mayo score for ulcerative colitis and the Crohn's Disease Activity Index—were recorded at baseline and week 8. The primary outcomes were changes in intestinal Candida burden, gut fungal‑community composition, bacterial diversity, microbial metabolites, and clinical disease activity scores. The open‑label, non‑randomized design reflects real‑world clinical practice but limits blinding.
# Temel bulgular
Among the 53 participants, fluconazole, but not nystatin, effectively reduced intestinal Candida burden and reshaped gut fungal‑community composition. Fluconazole treatment was accompanied by increased bacterial diversity and expansion of short-chain fatty‑acid‑producing taxa, as indicated by higher Shannon diversity indices and greater relative abundance of known SCFA producers. Additionally, fluconazole therapy restored anti‑inflammatory microbial metabolites and induced durable shifts in cross‑kingdom microbial networks, suggesting tighter integration between fungal and bacterial communities. Nystatin treatment did not produce significant changes in intestinal Candida levels, bacterial diversity, metabolite profiles, or clinical disease activity indices.
# Bulgular ne anlama geliyor?
The findings demonstrate that targeted gastrointestinal antifungal therapy with fluconazole can reshape the intestinal microbiota in IBD and establish a framework for implementing antifungal cotherapy in patients with fungal‑associated disease manifestations. The observed microbiome shifts—including increased bacterial diversity, expansion of beneficial SCFA‑producing taxa, and restoration of anti‑inflammatory metabolites—coincided with improved disease activity indices and a decreased risk of disease progression over the 8‑week follow‑up period. These results suggest that modulating the gut mycobiome may be a viable therapeutic strategy in IBD, particularly for patients with evidence of intestinal Candida overgrowth. However, causality cannot be confirmed, and the clinical significance of the microbiome changes requires validation in larger, controlled trials.
# Klinik önem
While the study shows promising associations between fluconazole‑induced microbiome changes and improved clinical outcomes, several limitations must be considered before clinical application. The open‑label design without blinding introduces performance and detection bias. The sample size of 53 limits generalizability, and the study population was limited to patients with mild oral thrush, so results may not represent all IBD patients. The 8‑week follow‑up is short for assessing long‑term outcomes, and there was no control group receiving no antifungal therapy for comparison. These findings suggest a need for larger, randomized, controlled trials to confirm efficacy, safety, and durability before recommending routine antifungal therapy in IBD management.
# Sınırlılıklar
The study has several notable limitations. The small sample size (n=53) limits generalizability to the broader IBD population. The open‑label design without blinding introduces performance and detection bias. The study population was limited to patients with mild oral thrush, which may not represent the full spectrum of IBD patients, including those without oral fungal overgrowth. The 8‑week follow‑up limits assessment of long‑term microbiome stability and clinical durability. There was no control group receiving no antifungal therapy, making it difficult to attribute observed changes solely to the intervention. Additionally, the study did not assess relapse rates or sustained benefits beyond the 8‑week period. These limitations underscore the need for cautious interpretation and further rigorous research.